NRX PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXPBusiness Wire • 05/05/22
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for AviptadilAccesswire • 04/22/22
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 TherapyBenzinga • 04/21/22
NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progressPRNewsWire • 04/21/22
NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial ResultsPRNewsWire • 03/31/22
NRXP Monday Deadline: ROSEN, A Top Ranked Law Firm, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/19/22
Deadline Monday Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/18/22
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 03/18/22
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and TreasurerPRNewsWire • 03/18/22
MONDAY DEADLINE: NRx Pharmaceuticals, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWPRNewsWire • 03/18/22
Deadline Monday Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/17/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPWPRNewsWire • 03/17/22
Deadline Monday Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/16/22
NRXP FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/15/22
Monday Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/15/22
DEADLINE NEXT WEEK: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWNewsfile Corp • 03/15/22
ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/14/22
7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/14/22
(NRXP; NRXPW) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading NRx Pharmaceuticals Class Action LawsuitNewsfile Corp • 03/14/22
ROSEN, A TOP RANKED FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPWPRNewsWire • 03/12/22
ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/10/22